One-month follow up of a randomized clinical trial-phase II study in 6 to <24 months old Indonesian subjects: Safety and immunogenicity of Vi-DT Typhoid Conjugate Vaccine

One-month follow up of a randomized clinical trial-phase II study in 6 to <24 months old Indonesian subjects: Safety and immunogenicity of Vi-DT Typhoid Conjugate Vaccine

Introduction: World Health Organization estimates the annual global incidence of typhoid fever at 11-21 million cases and approximately 128 000 to 161 000 deaths. The currently used Vi-polysaccharides (Vi-PS) vaccines have been proven to be safe and efficacious in children 2 years and above. However...

Full description

Bibliographic Details
Main Authors: Bernie Endyarni Medise, Soedjatmiko Soedjatmiko, Hartono Gunardi, Rini Sekartini, Hindra Irawan Satari, Sri Rezeki Hadinegoro, Angga Wirahmadi, Mita Puspita, Rini Mulia Sari, Jae Seung Yang, Arijit Sil, Sushant Sahastrabuddhe, Novilia Sjafri Bachtiar
Format: Article
Language:English
Published: Elsevier 2020-04-01
Series:International Journal of Infectious Diseases
Online Access:http://www.sciencedirect.com/science/article/pii/S1201971220300485

Similar Items

Similar Items